KaloBios calls it quits on its asthma drug after a Phase II flop – FierceBiotech

KaloBios calls it quits on its asthma drug after a Phase II flop
FierceBiotech
San Francisco's KaloBios ($KBIO) is hitting the breaks on one of its lead programs after the asthma treatment missed its primary endpoint in a mid-stage trial, sending the company's shares into a 30% tailspin. The drug, KB003, failed to significantly
KaloBios Pharma pulls plug on asthma drug, shares plungeReuters
KaloBios stock slides; to stop asthma studyMarketWatch
KaloBios: KB003 Fails To Meet Primary Goal In Phase 2 Asthma StudyRTT News
San Francisco Business Times (blog)
all 29 news articles »

View full post on asthma – Google News

Head quits after boy’s asthma death – The Press Association

Head quits after boy's asthma death
The Press Association
A head teacher has resigned after a schoolboy died from an asthma attack he suffered at school, a council has said. Eleven-year-old Sam Linton was left in a
Headteacher quits after asthma attack death of schoolboyManchester Evening News
Head quits over Stockport schoolboy's asthma deathBBC News
Headteacher at school where 'neglected' boy died of asthma attack in corridor Daily Mail
Eastwood Advertiser
all 59 news articles »

View full post on asthma – Google News